South Korea · Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 68.93 billion. The enterprise value is 84.60 billion.
| Market Cap | 68.93B |
| Enterprise Value | 84.60B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | Mar 12, 2026 |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 2.64% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +2.64% |
| Shares Change (QoQ) | -0.69% |
| Owned by Insiders (%) | 12.93% |
| Owned by Institutions (%) | 1.96% |
| Float | 12.66M |
Valuation Ratios
The trailing PE ratio is 14.09.
| PE Ratio | 14.09 |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | 29.65 |
| P/OCF Ratio | 10.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.07, with an EV/FCF ratio of 36.39.
| EV / Earnings | 16.92 |
| EV / Sales | 0.47 |
| EV / EBITDA | 11.07 |
| EV / EBIT | 19.79 |
| EV / FCF | 36.39 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.14 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 4.00 |
| Debt / FCF | 13.50 |
| Interest Coverage | 5.58 |
Financial Efficiency
Return on equity (ROE) is 5.18% and return on invested capital (ROIC) is 3.35%.
| Return on Equity (ROE) | 5.18% |
| Return on Assets (ROA) | 1.57% |
| Return on Invested Capital (ROIC) | 3.35% |
| Return on Capital Employed (ROCE) | 3.68% |
| Weighted Average Cost of Capital (WACC) | 4.56% |
| Revenue Per Employee | 730.91M |
| Profits Per Employee | 20.17M |
| Employee Count | 248 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 3.46 |
Taxes
In the past 12 months, Kukje Pharma has paid 687.52 million in taxes.
| Income Tax | 687.52M |
| Effective Tax Rate | 12.10% |
Stock Price Statistics
The stock price has decreased by -27.98% in the last 52 weeks. The beta is 0.25, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -27.98% |
| 50-Day Moving Average | 3,325.80 |
| 200-Day Moving Average | 4,158.48 |
| Relative Strength Index (RSI) | 53.57 |
| Average Volume (20 Days) | 96,603 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 181.27 billion and earned 5.00 billion in profits. Earnings per share was 240.18.
| Revenue | 181.27B |
| Gross Profit | 97.26B |
| Operating Income | 4.48B |
| Pretax Income | 5.68B |
| Net Income | 5.00B |
| EBITDA | 7.84B |
| EBIT | 4.48B |
| Earnings Per Share (EPS) | 240.18 |
Balance Sheet
The company has 15.72 billion in cash and 31.39 billion in debt, with a net cash position of -15.67 billion or -769.32 per share.
| Cash & Cash Equivalents | 15.72B |
| Total Debt | 31.39B |
| Net Cash | -15.67B |
| Net Cash Per Share | -769.32 |
| Equity (Book Value) | 99.37B |
| Book Value Per Share | 4,699.90 |
| Working Capital | 8.83B |
Cash Flow
In the last 12 months, operating cash flow was 6.69 billion and capital expenditures -4.37 billion, giving a free cash flow of 2.32 billion.
| Operating Cash Flow | 6.69B |
| Capital Expenditures | -4.37B |
| Depreciation & Amortization | 3.37B |
| Net Borrowing | 777.02M |
| Free Cash Flow | 2.32B |
| FCF Per Share | 114.17 |
Margins
Gross margin is 53.65%, with operating and profit margins of 2.47% and 2.76%.
| Gross Margin | 53.65% |
| Operating Margin | 2.47% |
| Pretax Margin | 3.13% |
| Profit Margin | 2.76% |
| EBITDA Margin | 4.33% |
| EBIT Margin | 2.47% |
| FCF Margin | 1.28% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.92%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.92% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 5 |
| Payout Ratio | 12.49% |
| Buyback Yield | -2.64% |
| Shareholder Yield | -1.71% |
| Earnings Yield | 7.26% |
| FCF Yield | 3.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 1.85 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.85 |
| Piotroski F-Score | 6 |